Patents by Inventor Shawn Wells
Shawn Wells has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12257240Abstract: Among others, the present invention provides methods and compositions for controlling blood glucose or weight, including a combination of (i) a therapeutically effective amount of berberine (BBR), or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, including dihydroberberine (DHB); and (ii) vitamin B12. The combination effectively ameliorates BBR or DHB side effects, including VB12 reduction, gastrointestinal discomfort, and slowed bowel movements, by promoting transcobalamin II receptors synthesis, decreasing homocysteine levels and maintaining intestinal balance, including short chain fatty acids content, gut microbiota diversity and richness.Type: GrantFiled: August 23, 2022Date of Patent: March 25, 2025Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.Inventors: Shawn Wells, Ronghua Yi, Mingru Wang, Kylin Liao
-
Publication number: 20240074996Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.Type: ApplicationFiled: July 21, 2023Publication date: March 7, 2024Applicant: Keto Innovations, LLCInventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao, Christian Unger
-
Patent number: 11903932Abstract: The present invention provides novel methods for enhancing muscle function in a mammal, the method includes administration to the mammal of a composition comprising therapeutically effective amount of dihydroberberine (DHB) or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. The present invention also provides a composition including therapeutically effective amount of dihydroberberine (DHB) or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, for enhancing muscle function. In addition, the present invention provides methods for preparing any compositions disclosed herein.Type: GrantFiled: October 28, 2022Date of Patent: February 20, 2024Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.Inventors: Mingru Wang, Ronghua Yi, Shawn Wells, Kylin Liao
-
Publication number: 20230364043Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.Type: ApplicationFiled: May 17, 2023Publication date: November 16, 2023Applicant: Keto Innovations, LLCInventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao, Christian Unger
-
Patent number: 11766416Abstract: Compositions of ?-aminoisobutyric acid (BAIBA), and methods of using the same to achieve a physiological objective, are provided. Compositions of BAIBA having enantiomeric purity, in which a selected proportion of the BAIBA is L-?-aminoisobutyric acid (L-BAIBA) and/or a selected proportion of the BAIBA is D-?-aminoisobutyric acid (D-BAIBA), are also provided.Type: GrantFiled: July 22, 2021Date of Patent: September 26, 2023Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.Inventors: Qilin Liao, Shawn Wells
-
Patent number: 11707465Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.Type: GrantFiled: August 9, 2022Date of Patent: July 25, 2023Assignee: Ortho-Nutra LLCInventors: Hector L. Lopez, Shawn Wells, Tim N. Ziegenfuss
-
Publication number: 20230149329Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.Type: ApplicationFiled: January 20, 2023Publication date: May 18, 2023Applicant: Keto Innovations, LLCInventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao
-
Publication number: 20230147386Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.Type: ApplicationFiled: August 9, 2022Publication date: May 11, 2023Applicant: Ortho-Nutra, LLCInventors: Hector L. Lopez, Shawn Wells, Tim N. Ziegenfuss
-
Publication number: 20230115966Abstract: The disclosed compositions, and methods relate to compositions for human consumption and comprising paraxanthine and a cholinergic agent and/or theanine. The disclosed compositions are useful promoting cognitive function, energy, athletic performance and providing neuroprotective anti-oxidative effects.Type: ApplicationFiled: October 13, 2022Publication date: April 13, 2023Inventors: Shawn Wells, Ralf Jager, Kylin Liao, Martin Purpura
-
Patent number: 11534426Abstract: Among others, the present invention provides novel methods for extending lifespan or improving healthspan in a mammal, which include administration to the mammal of a composition containing a therapeutically effective amount of ergothioneine, or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof.Type: GrantFiled: January 26, 2022Date of Patent: December 27, 2022Assignee: Nanjing Nutrabuilding Bio-tech Co., Ltd.Inventors: Joseph L. Evans, Qiru Fan, Shawn Wells, Kylin Liao
-
Patent number: 11491141Abstract: Glutathione deficiencies and deficiencies in glutathione synthetase activity, and therapeutic methods for the treatment thereof.Type: GrantFiled: January 6, 2022Date of Patent: November 8, 2022Assignee: NANJING NUTRABUILDING BIO-TECH CO., LTD.Inventors: Joseph L. Evans, Qiru Fan, Shawn Wells, Kylin Liao
-
Publication number: 20220331328Abstract: The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises 1-methylxanthine and optionally other compounds that modulate the effects of 1-methylxanthine. Uses for the 1-methylxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.Type: ApplicationFiled: April 7, 2022Publication date: October 20, 2022Inventors: Ralf Jäger, Martin Purpura, Shawn Wells, Kylin Liao
-
Publication number: 20220305019Abstract: Disclosed herein are methods for promoting weight loss in a subject by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain aspects, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further aspects, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, weight loss is promoted through inducing thermogenesis in the subject. In further embodiments, weight loss is promoted through enhancing lipolysis in the subject. According to certain implementations, administration of the composition to the subject decreases the respiratory quotient in the subject by at least about 10%.Type: ApplicationFiled: March 22, 2022Publication date: September 29, 2022Inventors: Martin Purpura, Ralf Jäger, Shawn Wells, Kylin Liao
-
Publication number: 20220305020Abstract: Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.Type: ApplicationFiled: March 28, 2022Publication date: September 29, 2022Inventors: Ralf Jäger, Martin Purpura, Shawn Wells, Kylin Liao
-
Patent number: 11426410Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.Type: GrantFiled: August 26, 2019Date of Patent: August 30, 2022Assignee: Ortho-Nutra, LLCInventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
-
Publication number: 20220249419Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.Type: ApplicationFiled: April 28, 2022Publication date: August 11, 2022Applicant: Keto Innovations, LLCInventors: Ryan P. Lowery, Jacob Wilson, Shawn Wells, Kylin Liao
-
Publication number: 20220202789Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.Type: ApplicationFiled: November 4, 2021Publication date: June 30, 2022Inventors: Ryan Lowery, Jacob Wilson, Shawn Wells
-
Patent number: 11337945Abstract: The present disclosure pertains to compositions and methods for the treatment and/or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD)/Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and/or physical performance levels and/or decreasing exertion during exercise in a subject by the administration of C5 ketones.Type: GrantFiled: August 1, 2017Date of Patent: May 24, 2022Assignee: Keto Innovations, LLCInventors: Ryan P. Lowery, Shawn Wells, Jacob Wilson, Kylin Liao
-
Publication number: 20220054441Abstract: Compositions of ?-aminoisobutyric acid (BAIBA), and methods of using the same to achieve a physiological objective, are provided. Compositions of BAIBA having enantiomeric purity, in which a selected proportion of the BAIBA is L-?-aminoisobutyric acid (L-BAIBA) and/or a selected proportion of the BAIBA is D-?-aminoisobutyric acid (D-BAIBA), are also provided.Type: ApplicationFiled: July 22, 2021Publication date: February 24, 2022Inventors: Qilin Liao, Shawn Wells
-
Patent number: 11026991Abstract: The disclosed compositions and methods relate to the increasing muscle mass, preventing muscle atrophy, promoting muscle growth, as well as treatment of various other conditions and diseases. In certain aspects, the disclosed compositions are comprised dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, disclosed compositions are administered to subjects in need thereof to increase muscle mass, prevent muscle atrophy, and/or promote muscle growth.Type: GrantFiled: April 18, 2019Date of Patent: June 8, 2021Assignee: Ingenious Ingredients, LPInventors: Martin Purpura, Ralf Jaeger, Shawn Wells, Kylin Lao, Anton Fliri